Evicto (2.5 - 7.5 kg)
Active substance
ATC code
Species
Cats (2.6 – 7.5 kg).
Indications
• Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven week of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in area to which the animal has access.
• Prevention of heartworm disease caused by Dirofilaria immitis with monthly administration. The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with the product. This product is not effective against adult D. immitis.
• Treatment of ear mites (Otodectes cynotis).
• Treatment of biting lice infestations (Felicola subrostratus)
• Treatment of adult roundworms (Toxocara cati)
• Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).
Dose to be administered and administration route
The product should be administered as a single application of a single dose delivering a minimum of 6 mg/kg selamectin. When concurrent infestations or infections in the same animal are to be treated with the veterinary medicinal product, only one application of the recommended 6 mg/kg dose should be administered at any one time.
The appropriate length of the treatment period for individual parasites is specified below.
Administer in accordance with the following table:
|
Cats (kg) |
Product |
Mg of selamectin dispensed |
Potency (mg/ml) |
Administered volume (nominal pipette size, ml) |
|
≤ 2.5 |
1 pipette of Evicto 15 mg for cats and dogs ≤2.5 kg |
15 |
60 |
0.25 |
|
2.6-7.5 |
1 pipette of Evicto 45 mg for cats 2.6-7.5 kg |
45 |
60 |
0.75 |
|
7.6-10.0 |
1 pipette of Evicto 60 mg for cats 7.6-10.0kg |
60 |
60 |
1.0 |
|
> 10 |
Appropriate combination of pipettes |
Appropriate combination of pipettes |
60 |
Appropriate combination of pipettes |
Flea treatment and prevention
Following administration of the veterinary medicinal product, the adult fleas on the animal are killed, no viable eggs are produced, and larvae (found only in the environment) are also killed. This stops flea reproduction, breaks the flea lifecycle and may aid in the control of existing environmental flea infestations in areas to which the animal has access.
For the prevention of flea infestations, the veterinary medicinal product should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestations in the litter up to seven weeks of age.
For use as part of a treatment strategy for flea allergy dermatitis the veterinary medicinal product should be administered at monthly intervals.
Prevention of heartworm disease
The veterinary medicinal product may be administered year-round or at least within one month of the animal’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season.
The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of the veterinary medicinal product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms. When replacing another heartworm preventive veterinary medicinal product in a heartworm disease prevention program, the first dose of the veterinary medicinal product must be given within a month of the last dose of the former medication.
Treatment of roundworm infections
A single dose of the veterinary medicinal product should be administered.
Treatment of biting lice
A single dose of the veterinary medicinal product should be administered.
Treatment of ear mites
A single dose of the veterinary medicinal product should be administered.
Treatment of hookworm infections
A single dose of the veterinary medicinal product should be administered.
Method and route of administration:
Spot-on use.
Apply to the skin at the base of the neck in front of the shoulder blades.
How to apply :
Remove the product pipette from its protective package.
1 - Holding the pipette upright, remove the cap.
2 - Invert the cap and place other end back onto applicator tip. Push the cap down to break the applicator seal.
Remove the cap prior to treatment application.
3 - Part the hair at the base of your animal’s neck in front of the shoulder blades to expose a small area of skin.
Apply the tip of the product pipette directly to the skin without massaging.
Squeeze the pipette firmly to empty the contents in one spot. Avoid contact between the product and your fingers.
Adverse reactions
Mild transient alopecia at the site of application has been reported rarely after use of the veterinary medicinal product in cats. Transient focal irritation may also be observed very rarely.
The alopecia and irritation are normally self-resolving, but symptomatic therapy may be applicable in some circumstances.
Local temporary clumping of the hair at the application site and/or an occasional appearance of a small quantity of a white powder has been reported rarely.
This is normal and will disappear typically within 24 hours of treatment administration and does not affect either the safety or efficacy of the veterinary medicinal product. If significant licking does occur, a brief period of hypersalivation may rarely be observed in cats.
As with other macrocyclic lactones, reversible neurological signs, including seizures, have been very rarely observed after use of the veterinary medicinal product.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Similar products
Showing 2 of 2 results
Evicto (2.5 - 7.5 kg)
